Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
World J Surg Oncol
2017 Jan 09;151:14. doi: 10.1186/s12957-016-1095-y.
Show Gene links
Show Anatomy links
TPX2 expression is associated with poor survival in gastric cancer.
Tomii C
,
Inokuchi M
,
Takagi Y
,
Ishikawa T
,
Otsuki S
,
Uetake H
,
Kojima K
,
Kawano T
.
???displayArticle.abstract???
BACKGROUND: Targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein required for microtubule formation in human cells. Several studies have demonstrated that TPX2 is overexpressed in multiple tumor types and promotes tumor growth and metastasis. However, there have been few reports regarding its role in gastric cancer. In this study, we evaluated TPX2 expression and investigated its correlations with gastric cancer clinicopathological features and prognosis.
METHODS: Tumor samples were obtained from 290 patients with gastric adenocarcinoma who had undergone gastrectomy. The expression of TPX2 protein was examined using immunohistochemical staining. TPX2 messenger RNA (mRNA) levels were evaluated using real-time quantitative reverse transcription PCR in 19 of the gastric cancer tumors and adjacent normal tissues.
RESULTS: The mRNA levels of TPX2 were significantly higher in gastric cancer tissues than in matched adjacent normal tissues (p = 0.004). In the immunohistochemical analysis, TPX2 overexpression was found in 123 (42.4%) of 290 patients. High TPX2 expression was positively associated with age, type of histology, depth of tumor, lymph node metastasis, stage, and remote metastasis or recurrence. High TPX2 expression was significantly associated with poorer disease-specific survival (p = 0.004) and relapse-free interval (p = 0.013).
CONCLUSIONS: Our results indicated that high TPX2 expression was associated with tumor progression and poor survival in gastric cancer.
Fig. 1. Targeting protein for Xenopus kinesin-like protein 2 (TPX2) mRNA expression in gastric cancerous and adjacent normal tissues. The median TPX2 mRNA level was significantly higher in gastric cancer than in the adjacent normal tissue in 19 patients (pâ=â0.004)
Fig. 2. Representative photomicrographs of immunostaining for targeting protein for Xenopus kinesin-like protein 2 (TPX2), demonstrating a negative staining in normal gastric epithelium, b negative staining in primary gastric carcinoma, c positive staining graded as low (<5% of tumor cells stained), and d positive staining graded as high (â¥5% of tumor cells stained). TPX2 protein was mainly localized within the nuclei of tumor cells. Images were captured at Ã200 magnification
Fig. 3. Kaplan-Meier curves for the disease-specific survival (DSS) of patients with targeting protein for Xenopus kinesin-like protein 2 (TPX2) expression. Patients with high TPX2 protein expression (nâ=â123) had significantly poorer DSS than those with low TPX2 expression (nâ=â167; pâ=â0.004)
Fig. 4. Kaplan-Meier curves for the relapse-free interval (RFI) of patients with targeting protein for Xenopus kinesin-like protein 2 (TPX2) expression. Patients with high TPX2 protein expression (nâ=â123) had significantly poorer RFI than those with low TPX2 expression (nâ=â167; pâ=â0.013)
Fig. 5. Kaplan-Meier curves for disease-specific survival (DSS) after recurrence of patients with low or high levels of targeting protein for Xenopus kinesin-like protein 2 (TPX2) expression. The log-rank test showed no significant difference between DSS and TPX2 expression in patients after recurrence (pâ=â0.52)
Aguirre-Portolés,
Tpx2 controls spindle integrity, genome stability, and tumor development.
2012,
Pubmed
Bian,
Short exposure to paclitaxel induces multipolar spindle formation and aneuploidy through promotion of acentrosomal pole assembly.
2010,
Pubmed
Carter,
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.
2006,
Pubmed
Chang,
The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer.
2012,
Pubmed
Cunningham,
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
2008,
Pubmed
Ferlay,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
2015,
Pubmed
Gruss,
Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells.
2002,
Pubmed
,
Xenbase
Hartgrink,
Gastric cancer.
2009,
Pubmed
Huang,
TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma.
2014,
Pubmed
,
Xenbase
Koizumi,
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
2010,
Pubmed
Koizumi,
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
2008,
Pubmed
Lengauer,
Genetic instabilities in human cancers.
1998,
Pubmed
Liang,
TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT.
2015,
Pubmed
Liang,
Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer.
2016,
Pubmed
,
Xenbase
Ma,
Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer.
2006,
Pubmed
Miwa,
Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.
2015,
Pubmed
Neumayer,
TPX2: of spindle assembly, DNA damage response, and cancer.
2014,
Pubmed
Niu,
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer.
2015,
Pubmed
Pérez de Castro,
Mitotic Stress and Chromosomal Instability in Cancer: The Case for TPX2.
2012,
Pubmed
Satow,
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
2010,
Pubmed
Shigeishi,
Expression of TPX2 in salivary gland carcinomas.
2009,
Pubmed
Sillars-Hardebol,
TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.
2012,
Pubmed
Warner,
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
2009,
Pubmed
Wei,
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer.
2013,
Pubmed